Zacks: Brokerages Anticipate Five Prime Therapeutics Inc (FPRX) Will Post Earnings of -$1.17 Per Share

Wall Street brokerages expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to report earnings of ($1.17) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Five Prime Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.42) and the highest estimate coming in at ($0.92). Five Prime Therapeutics posted earnings of ($1.54) per share in the same quarter last year, which indicates a positive year over year growth rate of 24%. The company is scheduled to announce its next quarterly earnings report on Monday, November 5th.

According to Zacks, analysts expect that Five Prime Therapeutics will report full year earnings of ($4.02) per share for the current financial year, with EPS estimates ranging from ($4.52) to ($3.65). For the next financial year, analysts forecast that the firm will report earnings of ($4.70) per share, with EPS estimates ranging from ($6.00) to ($3.89). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.30. Five Prime Therapeutics had a negative return on equity of 40.61% and a negative net margin of 206.02%. The company had revenue of $7.58 million for the quarter, compared to analysts’ expectations of $5.87 million.

Several brokerages have recently issued reports on FPRX. BidaskClub cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. Leerink Swann began coverage on Five Prime Therapeutics in a research report on Thursday, September 13th. They set an “outperform” rating and a $24.00 price target on the stock. ValuEngine cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 28th. Wedbush lifted their price target on Five Prime Therapeutics from $17.00 to $19.00 and gave the company a “hold” rating in a research report on Friday, August 10th. Finally, Zacks Investment Research cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $31.70.

Shares of FPRX stock opened at $14.30 on Thursday. Five Prime Therapeutics has a 1 year low of $12.52 and a 1 year high of $47.63.

Several institutional investors and hedge funds have recently added to or reduced their stakes in FPRX. Xact Kapitalforvaltning AB bought a new stake in shares of Five Prime Therapeutics during the 3rd quarter worth $145,000. MetLife Investment Advisors LLC boosted its stake in shares of Five Prime Therapeutics by 48.7% during the 2nd quarter. MetLife Investment Advisors LLC now owns 19,957 shares of the biotechnology company’s stock worth $316,000 after acquiring an additional 6,535 shares in the last quarter. Alambic Investment Management L.P. bought a new stake in shares of Five Prime Therapeutics during the 2nd quarter worth $351,000. Fox Run Management L.L.C. bought a new stake in shares of Five Prime Therapeutics during the 2nd quarter worth $379,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Five Prime Therapeutics by 17.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 25,032 shares of the biotechnology company’s stock worth $430,000 after acquiring an additional 3,782 shares in the last quarter. 86.30% of the stock is owned by institutional investors and hedge funds.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Featured Story: What are CEFs?

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply